Price
24.34
-5%52W Range
Market Cap
₹31.78 Cr
Traded: ₹0.05 Cr (0.16%) 0.0x
Free Float: ₹9.34 Cr (0.53% of FF traded)
Volume · 60D trend
20.42 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | -- | -- | -- | -- | -17.0% | -- |
| Sales | -- | -10.0% | -25.0% | -- | -16.0% | Stable |
| ROE | -- | +2.0% | -15.0% | -- | -- | Decelerating |
| Return | -- | -31.0% | -24.0% | +10.0% | -- | Accelerating |
Quarterly Results
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 24 | 19 | 26 | 25 | 17 | 25 | 33 | 18 | 38 | 19 | 33 | 56 | 39 | 47 |
| Expenses | 17 | 21 | 21 | 26 | 24 | 18 | 27 | 31 | 20 | 34 | 20 | 32 | 50 | 50 | 44 |
| Operating Profit | -2 | 3 | -3 | 0 | 1 | -1 | -2 | 2 | -2 | 3 | -2 | 2 | 7 | -10 | 3 |
| OPM % | -12.8% | 11.4% | -14.3% | 0.3% | 2.6% | -4.2% | -8.7% | 6.9% | -9.3% | 8.9% | -10.3% | 5.0% | 11.6% | -26.1% | 5.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 | 1 | -2 | -0 | 0 | 0 | 9 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 2 | 2 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 |
| Profit Before Tax | -6 | -1 | -6 | -3 | -3 | -4 | -6 | -1 | -4 | -4 | -6 | -3 | 2 | -6 | -3 |
| Tax % | -24.0% | 25.4% | -20.3% | -8.4% | -26.7% | -47.0% | -18.6% | 62.0% | -25.9% | -10.5% | -6.9% | -12.2% | 25.9% | -19.6% | -31.9% |
| Net Profit | -4 | -1 | -5 | -3 | -2 | -2 | -5 | -2 | -3 | -4 | -6 | -2 | 2 | -5 | -2 |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | -3.3 | -1.1 | -3.6 | -2.3 | -1.5 | -1.6 | -4.0 | -1.6 | -2.4 | -2.8 | -4.5 | -1.8 | 1.3 | -3.5 | -1.4 |
| Sales Growth (YoY) | -37.8% | 39.7% | -24.3% | -20.8% | 33.6% | -55.5% | 33.3% | -1.1% | -67.4% | -4.1% | -60.5% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -34.9% | 25.5% | -28.1% | 5.9% | 46.3% | -32.0% | -24.8% | 78.6% | -51.4% | 104.0% | -44.2% | -41.1% | 43.1% | -16.0% | -- |
| OP Growth (YoY) | -400.0% | 482.9% | -24.7% | -96.5% | 138.0% | -120.8% | -12.6% | 37.3% | -126.1% | 132.7% | -169.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | -172.8% | 200.0% | -3450.0% | -87.7% | 192.9% | 67.4% | -194.3% | 233.3% | -150.9% | 275.9% | -215.1% | -74.6% | 163.6% | -472.5% | -- |
| Profit Growth (YoY) | -111.0% | 33.0% | 8.0% | -41.0% | 35.0% | -8.0% | 12.0% | 10.0% | -275.0% | 59.0% | -233.0% | -188.0% | -50.0% | -187.8% | -240.2% |
| EPS Growth (YoY) | -111.0% | 32.9% | 8.3% | -41.3% | 34.5% | 43.6% | 12.6% | 10.1% | -275.4% | 20.7% | -233.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -206.6% | 70.9% | -61.1% | -46.8% | 2.5% | 60.2% | -148.1% | 31.9% | 16.1% | 38.3% | -155.1% | -232.8% | 138.0% | -159.6% | -- |
| OP Margin | -12.8% | 11.4% | -14.3% | 0.3% | 2.6% | -4.2% | -8.7% | 6.9% | -9.3% | 8.9% | -10.3% | 5.0% | 11.6% | -26.1% | 5.9% |
| Net Margin | -27.7% | -5.9% | -25.4% | -11.3% | -8.2% | -12.3% | -21.0% | -6.4% | -16.7% | -9.7% | -32.0% | -7.0% | 3.1% | -11.7% | -3.8% |
| Material Cost % | 68.0% | 57.0% | 69.0% | 68.0% | 66.0% | 62.0% | 65.0% | 65.0% | 63.0% | 66.0% | 62.0% | 65.0% | 65.0% | 93.0% | 64.0% |
| Employee Cost % | 26.0% | 15.0% | 23.0% | 17.0% | 18.0% | 25.0% | 18.0% | 14.0% | 23.0% | 11.0% | 24.0% | 15.0% | 10.0% | 15.0% | 11.0% |
| P/S | 0.38 | 0.44 | 0.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.60 | 0.77 | 0.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Financial Results 30.06.2026.
Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Standalone and Consolidated ....
Closure of Trading Window
Audited Financial Results for the quarter and year ended 31st March, 2026
Audited Results 31.03.2026
Annual Secretarial Compliance Report 31.03.2026.
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018
This is with reference to the email communication received from BSE Limited on April 09,2026 seeking clarification for a significant movement in the price of the securities of the company.
The Exchange has sought clarification from ANG Lifesciences India Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Intimation of closure of Trading Window.
Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
Unaudited Financial Results 31.12.2025.
Revised Annual Secretarial Report for the year ended 31.03.2025.
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve the Unaudited Standalone ....
Disclosure under Reg. 74(5) of SEBI (DP), Regulations, 2018.
Closure of Trading Window.
Unaudited Financial Results for the Quarter and Half year ended 30.09.2025.
Considered and approved the financial results for the quarter and half year ended 30th September 2025
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Pursuant to the Regulation ....
Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018
Scrutinizer''s Report along with voting Results
Appointment of Secretarial Auditor
Closure of Trading Window
Clarification on Price Movement
The Exchange has sought clarification from ANG Lifesciences India Ltd on September 12, 2025 with reference to significant movement in price, in order to ensure that investors have latest ....
Newspaper Advertisment for the Notice of 19th AGM
Annual Report for the FY 2024-25
Notice of AGM is Enclosed
Intimation of Book Closure
Intimation of AGM
This is to inform you under Regulation 30 and any other regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the Board of Directors of the Company ....
We hereby submitting the Unaudited Standalone & Consolidated Financial Results for the quarter ended 30.06.2025.
We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure ....
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 ,inter alia, to consider and approve the Standalone and Consolidated ....
Compliance certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.06.2025.
Closure of Trading Window.
Newspaper disclosure for the FY ended 31.03.2025.
Financial year Results for the year ended 31.03.2025
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the Board Meeting held today i.e. on Friday, ....
Pursuant to Regulation 24(A) of SEBI(LODR), Regulations, 2015, enclosed is the Annual Secretarial Compliance Report for the year ended on 31.03.2025
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve Pursuant to the Regulation ....
The company is not falling under Large Corporate Category as on 31st March, 2025.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Compliance certificate under Reg 74(5) of SEBI (DP) Regulations, for quarter ended 31.03.2025.
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with Company''s Code of Conduct to regulate, monitor and report the trading of equity ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Mr. Karun Singh, Group Opertaions Head of the Company had ....
Pursuant to Regulation 30 of SEBI (LODR), Regulations 2015, the Board of Directors at the meeting held on today March 12, 2025 have considered and appointed Ms. Harshita Aggarwal as the ....
Annual Reports
8Credit Ratings
6